Fibroblast activation protein-inhibitor-PET til monitorering af fibrotiske sygdomme

Rikke Helin Johnsen; Katja Bjerregaard Christensen; Saher B Shaker; Jann Mortensen; Christoffer Tandrup Nielsen

doi:10.61409/V04250306

Fibroblast activation protein-inhibitor-PET til monitorering af fibrotiske sygdomme

Rikke Helin Johnsen, Katja Bjerregaard Christensen, Saher B Shaker, Jann Mortensen, Christoffer Tandrup Nielsen^*

^*Corresponding author af dette arbejde

Abstract

Fibroblast activation protein inhibitor (FAPI) PET was initially developed for cancer diagnostics; however, studies suggest that FAPI PET is a promising modality in various fibrotic diseases, including interstitial lung disease, fibrotic myocardial diseases, and rheumatic diseases such as rheumatoid arthritis, IgG4-related disease, and systemic scleroderma. There are limited studies on the subject, but this review finds that FAPI PET can accurately and specifically visualise active fibrosis and holds potential for monitoring treatment response and differentiation between inflammation and fibrosis.

Bidragets oversatte titel	Fibroblast activation protein inhibitor PET for monitoring fibrotic diseases
Originalsprog	Dansk
Artikelnummer	V04250306
Tidsskrift	Ugeskrift for Laeger
Vol/bind	187
Udgave nummer	45
Antal sider	8
ISSN	0041-5782
DOI	https://doi.org/10.61409/V04250306
Status	Udgivet - 3 nov. 2025

Emneord

Humans
Fibrosis/diagnostic imaging
Positron-Emission Tomography/methods
Lung Diseases, Interstitial/diagnostic imaging
Scleroderma, Systemic/diagnostic imaging
Serine Endopeptidases/metabolism
Gelatinases/metabolism
Endopeptidases
Rheumatic Diseases/diagnostic imaging
Arthritis, Rheumatoid/diagnostic imaging
Immunoglobulin G4-Related Disease/diagnostic imaging
Cardiomyopathies/diagnostic imaging
Membrane Proteins

Adgang til dokumentet

10.61409/V04250306Licens: CC BY-NC-ND

Citationsformater

@article{800324d8233c405c97d5aa6bb458df81,

title = "Fibroblast activation protein-inhibitor-PET til monitorering af fibrotiske sygdomme",

abstract = "Fibroblast activation protein inhibitor (FAPI) PET was initially developed for cancer diagnostics; however, studies suggest that FAPI PET is a promising modality in various fibrotic diseases, including interstitial lung disease, fibrotic myocardial diseases, and rheumatic diseases such as rheumatoid arthritis, IgG4-related disease, and systemic scleroderma. There are limited studies on the subject, but this review finds that FAPI PET can accurately and specifically visualise active fibrosis and holds potential for monitoring treatment response and differentiation between inflammation and fibrosis.",

keywords = "Humans, Fibrosis/diagnostic imaging, Positron-Emission Tomography/methods, Lung Diseases, Interstitial/diagnostic imaging, Scleroderma, Systemic/diagnostic imaging, Serine Endopeptidases/metabolism, Gelatinases/metabolism, Endopeptidases, Rheumatic Diseases/diagnostic imaging, Arthritis, Rheumatoid/diagnostic imaging, Immunoglobulin G4-Related Disease/diagnostic imaging, Cardiomyopathies/diagnostic imaging, Membrane Proteins",

author = "Johnsen, {Rikke Helin} and Christensen, {Katja Bjerregaard} and Shaker, {Saher B} and Jann Mortensen and Nielsen, {Christoffer Tandrup}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2025",

month = nov,

day = "3",

doi = "10.61409/V04250306",

language = "Dansk",

volume = "187",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "45",

}

TY - JOUR

T1 - Fibroblast activation protein-inhibitor-PET til monitorering af fibrotiske sygdomme

AU - Johnsen, Rikke Helin

AU - Christensen, Katja Bjerregaard

AU - Shaker, Saher B

AU - Mortensen, Jann

AU - Nielsen, Christoffer Tandrup

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2025/11/3

Y1 - 2025/11/3

N2 - Fibroblast activation protein inhibitor (FAPI) PET was initially developed for cancer diagnostics; however, studies suggest that FAPI PET is a promising modality in various fibrotic diseases, including interstitial lung disease, fibrotic myocardial diseases, and rheumatic diseases such as rheumatoid arthritis, IgG4-related disease, and systemic scleroderma. There are limited studies on the subject, but this review finds that FAPI PET can accurately and specifically visualise active fibrosis and holds potential for monitoring treatment response and differentiation between inflammation and fibrosis.

AB - Fibroblast activation protein inhibitor (FAPI) PET was initially developed for cancer diagnostics; however, studies suggest that FAPI PET is a promising modality in various fibrotic diseases, including interstitial lung disease, fibrotic myocardial diseases, and rheumatic diseases such as rheumatoid arthritis, IgG4-related disease, and systemic scleroderma. There are limited studies on the subject, but this review finds that FAPI PET can accurately and specifically visualise active fibrosis and holds potential for monitoring treatment response and differentiation between inflammation and fibrosis.

KW - Humans

KW - Fibrosis/diagnostic imaging

KW - Positron-Emission Tomography/methods

KW - Lung Diseases, Interstitial/diagnostic imaging

KW - Scleroderma, Systemic/diagnostic imaging

KW - Serine Endopeptidases/metabolism

KW - Gelatinases/metabolism

KW - Endopeptidases

KW - Rheumatic Diseases/diagnostic imaging

KW - Arthritis, Rheumatoid/diagnostic imaging

KW - Immunoglobulin G4-Related Disease/diagnostic imaging

KW - Cardiomyopathies/diagnostic imaging

KW - Membrane Proteins

U2 - 10.61409/V04250306

DO - 10.61409/V04250306

M3 - Review

C2 - 41263171

SN - 0041-5782

VL - 187

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 45

M1 - V04250306

ER -

Fibroblast activation protein-inhibitor-PET til monitorering af fibrotiske sygdomme

Abstract

Emneord

Adgang til dokumentet

Fingeraftryk

Citationsformater